Analyst Price Target is $5.67
▲ +258.65% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Chemomab Therapeutics in the last 3 months. The average price target is $5.67, with a high forecast of $7.00 and a low forecast of $4.00. The average price target represents a 258.65% upside from the last price of $1.58.
Current Consensus is
Buy
The current consensus among 4 contributing investment analysts is to buy stock in Chemomab Therapeutics. This rating has held steady since April 2024, when it changed from a Moderate Buy consensus rating.